hIPSC Core Facility
• Derivation of hIPSC lines for disease modelling.
The core facility has successfully generated high-quality iPSCs from more than 500 patients. Upon request, the core facility can derive hIPSCs from dermal fibroblast cultures or peripheral blood mononuclear cells (PBMCs), using non-integrative reprogramming techniques. The resulting pluripotent stem cells can then be differentiated into cell types affected by disease for basic studies and drug screening applications. Derivation submission form
• Genome editing using CRISPR-Cas9 technology.
CRISPR-Cas9 has emerged as a powerful tool to generate hIPSC lines with knockout for specific genes and to correct disease-causing mutations, thereby creating isogenic cell lines for disease modelling. The core facility has successfully applied this technology to generate knock out and knock in hIPSCs. We can assist on any stage of the process including designing and cloning of the constructs, transfection and genotyping.
• Training for IPSC derivation, IPSC culture and genome editing.
The BRC hIPSC core facility provides hands-on training for derivation, characterization, differentiation and genome editing of hIPSCs.
• Available resources:
- Control hIPSC lines from healthy donors
- Protocols for IPSC derivation, culture and differentiation
- Conditional gene knockdown or knockout hIPSC lines (Bertero A, et al., Development. 2016 Dec 1;143(23):4405-4418. PMID: 27899508)
- Reporter lines (GFP)
Future activities of the hIPSCs core facility will also include the derivation of primary organoid culture from adult organs including liver and gut.
If you would like more information about NIHR Cambridge BRC, please contact us.